Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

non-immunoglobulin-mediated membranoproliferative glomerulonephritis - Clinical Profile, Treatments & Trials | Kisho | Kisho

Rare Disease

non-immunoglobulin-mediated membranoproliferative glomerulonephritis

MONDO:0018013

Also known as:C3 glomerulopathynon-Ig-mediated MPGNnon-Ig-mediated membranoproliferative glomerulonephritis

Find Clinical TrialsTrials

Overview

Treatments3 FDA approved

Clinical Trials13 registered · 8 recruiting

Clinical Presentation

Built from Human Phenotype Ontology (HPO) phenotype annotations and GeneReviews clinical descriptions. Features represent findings documented across known cases — not an exhaustive list of possible symptoms.

Features include very common findings: Blood in the urine (hematuria); and common findings: Protein in the urine (proteinuria), Membranoproliferative glomerulonephritis, Hypertension, and Elevated creatinine (kidney function marker) (elevated circulating creatinine concentration) and others. 23 total HPO annotations.

Organ System	Phenotype Count	Example Features
Kidneys and urinary system	9	Blood in the urine (hematuria), Protein in the urine (proteinuria), Membranoproliferative glomerulonephritis

Diagnosis

Biomarker and diagnostic research for non-immunoglobulin-mediated membranoproliferative glomerulonephritis has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

2 FDA-approved treatments are available for non-immunoglobulin-mediated membranoproliferative glomerulonephritis, including PEGCETACOPLAN (EMPAVELI, approved 2021) and IPTACOPAN (FABHALTA, approved 2023). An additional 3 compounds hold orphan drug designation.

Approved Therapies

Brand Name	Generic Name	Mechanism	Approved

Prognosis

Phenotype severity distribution: 1 very common feature, 11 common features.

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

13 clinical trials registered, 8 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 2 PHASE3, 4 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT06209736](https://clinicaltrials.gov/study/NCT06209736)

Data assembled from 6 of 12 sources · Last updated Sep 19, 2026, 9:41 PM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:329918

GARD

Genetic and Rare Diseases Info Center

GARD:17507

Questions for Your Care Team

→What are the benefits and potential side effects of EMPAVELI for managing non-immunoglobulin-mediated membranoproliferative glomerulonephritis?
→Are any of the 13 active clinical trials a good fit for my situation?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Brand Name	Generic Name	Sponsor	Designated	Exclusivity End	Designation Status
synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA	synthetic double-strand small interfering ribonucleic acid (siRNA) oligonucleotide drug directed against C3 messenger RNA	Silence Therapeutics plc	2022	—	Designated
avacopan	avacopan	ChemoCentryx, Inc.	2017	—	Withdrawn
S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide	S3,S13-cyclo(D-tyrolsyl-L-isoleucyl-L-cysteinyl-L-valyl-1-methyl-L-tryptophyl-L-glutaminyl-L-aspartyl-L-tryptophyl-N-methyl-L-glycyl-L-alanyl-L-histidyl-L-arginyl-L-cysteinyl-N-methyl-L-isoleucinamide	Amyndas Pharmaceuticals S.A	2015	—	Designated

Research Type	Count	% of Total
Research summaries	52	39%
Disease patterns and progression	23	17%
Patient case studies	20	15%
Laboratory research	15	11%
Other research	9	7%
Clinical study results	7	5%
Testing and diagnosis research	3	2%
New treatment approaches	3	2%

Kisho

non-immunoglobulin-mediated membranoproliferative glomerulonephritis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications

non-immunoglobulin-mediated membranoproliferative glomerulonephritis

Overview

Clinical Presentation

Diagnosis

Treatment

Approved Therapies

Prognosis

Research Landscape

Medical References

External Resources

Orphanet

GARD

Subtypes

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Explore clinical features

Orphan Drug Designations

Clinical Trials

Recent Publications